Acute myeloid leukemia in children
Conditions
Interventions
Venetoclax+CRNIT GROUP:The combination of targeted therapy and chemotherapy was applied in the treatment of reduction of volume, induction therapy, consolidation therapy and maintenance therapy, and v
Venetoclax GROUP:The combination of targeted therapy and chemotherapy was applied in the treatment of reduction of volume, induction therapy, consolidation therapy and maintenance therapy, and only Ve
Sponsors
Beijing Children's Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed of AML; 2. Patients younger than 18 years old; 3. Patients who haven't received pre-treatment, except for those who receive single IT injection or Hydroxycarbamide or low-dose Ara-c for Leukocytosis (no more than 300mg/m2); 4. Patients or/and their guardian who have signed the Informed Consent Form.
Exclusion criteria
Exclusion criteria: 1. Junior Myelomonocytic Leukemia; 2. Mixed Phenotype Acute Leukemia; 3. Acute Promyelocytic Leukemia; 4. Patients who received any anti-tumor treatment within 2 weeks, except for those who received single IT injection or Hydroxycarbamide or low-dose Ara-c for Leukocytosis; 5. Patients complicated with any other diseases or psychiatric disease that could affect their safety and compliance, informed consent, participation, follow-up or interpretation of results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS;EFS;DFS;Complete response rate after induction therapy;MCR rate after induction therapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to complete remission after treatment;Time to MCR after treatment; | — |
Countries
China
Contacts
Public ContactZheng huyong
Beijing Children's Hospital, Capital Medical University
Outcome results
None listed